UNITED STATES                                  
                       SECURITIES AND EXCHANGE COMMISSION                       
                             Washington, D.C. 20549                             


                            SCHEDULE 14AINFORMATION                             
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
                                (Amendment No.)                                 


Filed by theRegistrant
Filed by a Party other than the Registrant
Check the appropriate box:


 Preliminary Proxy Statement



 Confidential, for Use of the Commission Only (as permitted by Rule
 14a-6(e)(2))                                                      



 Definitive Proxy Statement



 Definitive Additional Materials



 Soliciting Material Pursuant to (s)
 240.14a-12                         

                                 XBiotech Inc.                                  
                (Name of Registrant as Specified In Its Charter)                
Payment of Filing Fee (Check the appropriate box)


 No fee required.



 Fee paid previously with preliminary materials.



 Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and
 0-11.                                                                                        





-------------------------------------------------------------------------------

XBiotech Inc. Thursday, June 20,2024 10:00 AM, Central Time Annual Meeting to 
be held live via the Internet - please visitwww.proxydocs.com/XBIT for more 
details You must register to attend the meeting online and/or partidpate at 
wvew.proxydocs.com/XBIT For a convenient way to view proxy materials, VOTE, 
and obtain directions to attend the meeting go towww.proxydocs.com/XBIT To 
vote your proxy while visiting this site, you will need the 12 digit control 
number in the box below. This communication presents only an overview of the 
more complete proxy materials that are available shares. We toencourage you on 
the you Internet. to access This and is notreview a ballot. all ofYou the 
cannot important use this information notice to contained vote your in the 
proxy materials before voting. Under United States Securities and 
ExchangeCommission rules, praxy materials do not have to be delivered in 
paper. Proxy materials can be distributed by making them available on the 
internet. If you want to receive a paper or e-mail copy of the proxy material, 
you must request one. There isno charge to you for requesting a copy. In order 
to receive a paper package in time for this year's meeting,you must make this 
request on or before June 10, 2024. Meeting Materials: Notce of Meeting and 
Proxy Statement & Annual ReportorForm 10-K To order paper materials, use one 
of the following methods. g www.investorelections.com/XBIT 1-866-648-8133 
paper@investorelections.com * tfrequesing material by ermal, please send 2 
blank emailwih he 12 digt contol number (located below)in he subject Ine. No 
other requests, instuctonsOR other inquiries should be incudedwith your email 
requesting masters Your control number Have the 12 digit control number 
located in the box above available when you access he website and follow 
theinstructions. SEE REVERSE FOR FULL AGENDA Copyright (c) 2024 BetaNxT, Inc. 
or its affiliates. All Rights Reserved

-------------------------------------------------------------------------------

THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1,2 AND3 XBiotech 
Inc. Annual Meeting of Stockholders 1. To elect the five(5) nominees for 
director named herein to serve until the next annual meeting and their 
successors are duly elected and qualified. 1.01 John Simard 1.02 W. Thorpe 
McKenzie 1.03 Jan-Paul Waldin, Esq. 1.04 Donald H. MacAdam 1.05 Peter Libby, 
M.D. 2.To ratify the selection by the Audit Committee of the Board of 
Directors of Whitley Penn LLP as the independent registered public accounting 
firm of the Company for its fiscal year ending December 31, 2024. 3. To 
approve, on an advisory basis, thecompensation of the Company's named 
executive officers. To conduct any other business properly brought before the 
meeting.
{graphic omitted}
{graphic omitted}